MedPath

Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers

Not Applicable
Recruiting
Conditions
Cancer
Malignant Neoplasm
Registration Number
NCT05823740
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Brief Summary

The primary objective of this study is to evaluate the feasibility and acceptability of obtaining repeated measurements of lean muscle mass, physical function, and biological aging in children receiving active cancer therapy. The secondary objective is to evaluate the feasibility of using the D3-creatine dilution method (D3Cr) to measure skeletal muscle mass in children with cancer.

Assessments will be collected at diagnosis, once during active treatment, and end of treatment in coordination with routine imaging to monitor changes in study outcomes during active cancer treatment. Key sociodemographic, treatment and health-related factors will be abstracted from the medical record.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
The feasibility of collecting body composition assessmentsup to 12 months

The feasibility of collecting body composition assessments will be measured as the % of participants completing all 3 assessments for each modality: D3-Creatine dilution method (D3Cr), Bioelectrical impedance Analysis (BIA), medical imaging (computerized tomography (CT), or magnetic resonance imaging (MRI), or positron emission tomography (PET).

The feasibility of collecting individual physical function assessmentsup to 12 months

The feasibility of collecting individual physical function assessments will be measured as the % of participants completing all 3 assessments for each modality namely the 6-Minute Walk Test (6MWT), Timed Up and Go (TUG), 30-second Sit-to-Stand (STS), Hand Grip Strength (GS)) at multiple time points during cancer therapy.

Secondary Outcome Measures
NameTimeMethod
Feasibility of collecting repeated measurements of biological aging (p16 expression)up to 12 months

The feasibility of collecting repeated measurements of biological aging (p16 expression) will be evaluated as % of participants completed both pre-treatment and post-treatment assessments.

The acceptability of the studyup to 12 months

The acceptability of the study will be evaluated as the number of subjects approached and enrolled and number of subjects that withdraw from the study.

Trial Locations

Locations (1)

UNC Lineberger Comprehensive Cancer Center

🇺🇸

Chapel Hill, North Carolina, United States

UNC Lineberger Comprehensive Cancer Center
🇺🇸Chapel Hill, North Carolina, United States
Daniel Kleissler
Contact
919-928-6231
daniel_kleissler@med.unc.edu
Jessica Benjamin-Eze, DO
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.